Neoplasms

Immune System Diseases

All Conditions

Skin and Connective Tissue Diseases

Rare Diseases

Mastocytosis

Mastocytosis, Systemic

Neoplasms, Connective Tissue

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Mast Cell Activation Disorders

Systemic Mastocytosis

Suning Chen, Professor

Suning Chen

The Registry for Patients With Systemic Mastocytosis in China is a voluntary, observational database that will capture demographic, socioeconomic, and disease information with systemic mastocytosis. No experimental intervention is involved.

Systemic Mastocytosis (SM) is an extremely rare and heterogeneous spectrum of diseases characterized by the buildup of genetically altered mast cells in bone marrow sections and/or other extracutaneous organ(s). SM has not been given enough attention in China at present, and the epidemiological data in China are not clear. To understand the epidemiological characteristics and distribution patterns of SM patients in China. To establish a China-wide database platform for registering SM patients and to develop uniform registration standards and processes; to register SM patients who meet the enrollment criteria nationwide through a multicenter collaborative approach and to collect information on their baseline data, clinical manifestations, laboratory tests, treatment regimens, and follow-up results; to perform quality control and data cleansing on the information collected in the registration database, as well as to perform descriptive and inferential statistical analyses.

A Registry for Patients With Systemic Mastocytosis in China

Mastocvtosis Collaborative Network of China: A Registry for Patients With Systemic Mastocytosis

Evaluation of the morbidity rate over 2 years of Systemic Mastocytosis and its subtypes including Bone marrow mastocytosis (BMM), Indolent SM, Smoldering SM, Aggressive SM, SM with an associated hematologic neoplasm and Mast cell leukemia. (cases per 1,000 individuals per year)

1. The median age of Systemic Mastocytosis patients (year-old);
2. The sex distribution of Systemic Mastocytosis patients (M/F ratio\[0-1\]);
3. The ECOG score of Systemic Mastocytosis patients (score\[0-5\]);
4. The geographic distribution of Systemic Mastocytosis patients (% per province\[0-100\]);

1. The neutrophils, eosinophils, basophils, and mast cells in WBC classification (%);
2. The proliferative degree in sections of BM (%);
3. The ratio of mast cells in BM smear and FCM (%);
4. The ratio of expression of CD25, CD2, and CD30 in FCM (%);
5. The serum tryptase level(%).

1. The incidence of extramedullary organ infiltration including skin, bone and other organs (%);
2. The incidence of enlarged liver (%);
3. The incidence of enlarged spleen (%);
4. The incidence of enlarged lymphnodes (%);
5. The incidence of hypoproteinemia and loss weight (%).

1. The rate of eligible complete remission (CR) patients(%);
2. The rate of eligible partial remission (PR) patients(%);
3. The rate of eligible clincal improvement (CI) patients(%);
4. The rate of eligible stable disease (SD) patients(%);
5. The rate of eligible progressive disease (PD) patients(%);
6. The rate of eligible loss of reponse (LOR) patients(%).

1. Overall survival (months): Measured the time from enrollment to the date of the last follow-up or death;
2. Event-free survival (months): Measured the time from the date of attaining CR1 until the first relapse, death, or the final follow-up day.

The First Affiliated Hospital of Soochow University

Director, Clinical Professor

Heart and Blood Diseases

Diseases and Abnormalities at or Before Birth

Nutritional and Metabolic Diseases

Symptoms and General Pathology

Angioedema

Angioedemas, Hereditary

Urticaria

Skin Diseases

Skin Diseases, Vascular

Hypersensitivity

Hypersensitivity, Immediate

Vascular Diseases

Deficiency Diseases

Hereditary Complement Deficiency Diseases

Immunologic Deficiency Syndromes

Primary Immunodeficiency Diseases

Genetic Diseases, Inborn

Syndrome

Hereditary Angioedema

All Drugs and Chemicals

Complement C1 Inhibitor Protein

Angiotensin-Converting Enzyme Inhibitors

Broad definition: Angioedema due to urticaria (histaminergic/mast-cell) or non-urticarial (non-histaminergic) etiology Narrow definition: non-urticarial angioedema - distinguishing between C1-Inhibitor deficiency/dysfunction, and Angioedema with normal levels of C1-Inhibitor.

Broad definition: No medical history of angioedema of any kind, including urticaria (histaminergic) or drug-induced angioedema (e.g. ACE-Inhibitor angioedema)

Venipuncture

Henry Li, MD, PhD

Joseph Chiao, MD

Lili Wan, PhD

This clinical trial aims to evaluate and compare novel and commercially available diagnostic assays through blood tests for the differential diagnosis and comprehensive assessment of patients experiencing recurrent angioedema attacks, including both urticarial and non-urticarial angioedema. The primary objective is to assess the efficiency of novel diagnostic assays, both individually and in combination, in comparison to currently available commercial tests. The ultimate goal is to establish the feasibility of developing an affordable and accurate laboratory test capable of diagnosing the diverse etiological manifestations of angioedema.

Purpose: The purpose of this prospective non-interventional non-randomized diagnostic study is to first identify patients with recurrent angioedema attacks, then collect their blood samples (venipuncture) and ultimately send the samples to specialized laboratories to perform multiple diagnostic assays, novel and traditional, that can distinguish the various forms of angioedema (urticaria and non-urticarial symptoms and signs), and healthy subjects.

Methods and Materials: Blood specimen collection from a total of 300 patients with recurrent angioedema attacks, and 300 healthy volunteers without a history of angioedema attacks. Laboratory testing will include assays on multiple platforms. Complement testing via immunoassay and biochemistry techniques. Flow Cytometry using multiple markers. Mass Spectrometry that includes bradykinin metabolite and histamine detection. Molecular Genetics include Sanger sequencing, Next Generation Sequencing (NGS), and digital PCR.

Patient population: Study participants to be screened who have a history of recurrent angioedema incidents as well as a population of healthy subjects. A medical history will be documented after obtaining informed patient consent to enter into the clinical trial. Each enrolled participant will have blood collected as whole blood, plasma and serum via venipuncture.

Eligibility criteria (inclusion) for sample collection (angioedema subject):

* Understand and sign the informed consent form before starting any study procedure.
* Adult or Child: aged 12 years of age or older (consent must be signed by a single parent or legal guardian).
* Angioedema symptoms and signs by medical history, or previous laboratory diagnostic testing, or genetically proven cases (e.g. SERPING1 or other mutation). Patients can be on active medication for the treatment and prophylaxis of angioedema. Angioedema cases must be verified by a clinician from IAA.
* Able to perform and endure safely the collection of peripheral blood samples (venipuncture), or optionally agree to have additional testing via a skin punch biopsy.

Eligibility criteria (inclusion) for sample collection (for healthy participant/subject):

* Understand and sign the informed consent form before starting any study procedure.
* Adult or Child: aged 12 years of age or older (consent must be signed by a single parent or legal guardian).
* No history of any angioedema symptoms and signs, previous laboratory diagnostic testing, or genetically proven cases.
* Able to perform and endure safely the collection of peripheral blood samples (venipuncture), or optionally agree to have additional testing via a skin punch biopsy.
* Not on ACE inhibitors and if on blood pressure medication, to indicate the drug(s).

Exclusion Criteria (for all participants):

* Minor: 11 years of age or younger.
* Cannot read or understand the informed consent form and instructions.
* Unable to perform the peripheral blood sample collection.
* Taking medications contraindicated for testing.
* History of excessive bleeding after phlebotomy, e.g. Hemophilia.
* Contraindication due to other health-related issues.

Angioedema Biomarker Research Study

The analyzed data will be published in a peer-reviewed journal and preliminary results published on clinicaltrials.gov website

Determining whether novel test methods can be more efficient than currently available or traditional laboratory test for angioedema diagnosis

Genetic testing that include know angioedema mutations, such as SERPING1

Mass Spectrometry analysis of plasma for bradykinin metabolites

development of novel immunoassay biomarkers, such as the detection of cleaved HMWK

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Registry for Patients With Systemic Mastocytosis in China	NCT06013683	Systemic Mastoc...		-	The First Affiliated Hospital of Soochow University
Angioedema Biomarker Research Study	NCT06210698	Angioedema Angioedemas, He... Urticaria Mastocytosis ACE Inhibitor-I... C1 Inhibitor De... Systemic Mastoc... Indolent System...	Venipuncture	12 Years - 75 Years	Foundation For Rare Disease Research

Spots Global Cancer Trial Database for systemic mastocytoses